Research programme: type IIb sodium-phosphate co-transporter inhibitors - Sanofi

Drug Profile

Research programme: type IIb sodium-phosphate co-transporter inhibitors - Sanofi

Alternative Names: NaP2 inhibitors; NaPi2b inhibitors; Npt2b inhibitors; RDX 002; SLC34A2 inhibitors

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ardelyx
  • Developer Sanofi
  • Class Small molecules
  • Mechanism of Action Type IIb sodium-phosphate cotransporter protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hyperphosphataemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperphosphataemia in USA
  • 01 Sep 2015 Sanofi decides to terminate its license for NaP2b phosphate inhibitor programme worldwide
  • 24 Feb 2014 Ardelyx licenses NaP2b phosphate inhibitor programme to Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top